Australasian contract for supplying CamPROBE prostate biopsy equipment

Australasian contract for supplying CamPROBE prostate biopsy equipment

The medical landscape in Australia and New Zealand is set to undergo a significant transformation, as the innovative CamPROBE device, a potential game-changer in prostate cancer diagnostics and biopsies, becomes more accessible to urologists and patients in these regions.

Developed by Professor Vincent Gnanapragasam and his team at the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, CamPROBE is poised to enhance the patient and healthcare experience, given the increasing global demand for prostate cancer biopsies and diagnostics.

This groundbreaking device is designed to facilitate transperineal prostate biopsies under local anaesthetic, offering several significant benefits. One such advantage is its integrated local anaesthetic delivery system. CamPROBE allows for simultaneous local anaesthetic delivery through an integrated needle during biopsy acquisition, minimising patient discomfort by precisely delivering anaesthetic where needed, without the need for additional procedures.

CamPROBE provides an alternative to traditional transrectal ultrasound (TRUS) biopsies, offering observational evidence that transperineal approaches, such as those enabled by CamPROBE, may have a higher cancer detection rate, particularly for tumours located in areas less accessible by TRUS biopsy.

The use of local anaesthetic transperineal biopsy (LATP) with devices like CamPROBE reduces risks associated with transrectal biopsies, such as infection, as the transperineal route avoids rectal flora. This improvement in patient safety and comfort is further bolstered by CamPROBE's design, which uses only two body entry puncture points, compared to transrectal and other transperineal devices.

The recent appointment of Murray Medical Solutions as the exclusive distributor of CamPROBE in Australia and New Zealand marks a significant milestone in the device's journey. Murray Medical Solutions, known for supplying innovative solutions in urology and other therapy-area products in Australasia, will make the CamPROBE system more accessible, potentially improving biopsy practices and patient outcomes on a wider scale.

Stuart Thomson, Vice President of Business Development at Murray Medical Solutions, expressed his excitement about the new partnership, stating, "We are thrilled to bring CamPROBE to Australia and New Zealand. This partnership aligns with our tradition of improving patients' quality of life by providing cutting-edge solutions."

Terry Parlett, Commercialisation Director at Cambridge Enterprise, shared similar sentiments, expressing excitement about the CamPROBE system becoming available to patients in the Australasian market through this partnership.

The partnership between Murray Medical Solutions, JEB Technologies, and Medovate allows urologists across Australia and New Zealand to offer their patients access to the CamPROBE technology. This collaboration is another example of how an innovative clinical-academic like Vincent can turn an idea into a product that positively impacts patients' lives.

In conclusion, the CamPROBE device offers the potential to revolutionise prostate biopsy procedures in Australia and New Zealand by making them safer, more effective, and more comfortable for patients, while also facilitating earlier and more accurate cancer detection. The partnership between Murray Medical Solutions and the creators of CamPROBE is a significant step towards enhancing patient care in the field of transperineal prostate biopsy in these regions.

1. The integration of health tech innovations, like the CamPROBE device, into the medical landscape in Australia and New Zealand is expected to significantly impact patient care, particularly in the diagnosis and biopsy of prostate cancer.
2. Developed by Professor Vincent Gnanapragasam and his team, CamPROBE is designed to enhance digital health practices, offering advantages such as an integrated local anaesthetic delivery system for more comfortable biopsies.
3. In the realm of medical devices, CamPROBE provides an alternative to traditional transrectal ultrasound (TRUS) biopsies, with observational evidence suggesting a higher cancer detection rate for tumors that are less accessible by TRUS biopsy.
4. This collaboration between Murray Medical Solutions, JEB Technologies, and Medovate brings the CamPROBE system to the Australasian market, potentially improving patient care, medical-condition detection, and health-and-wellness outcomes through safer, more effective, and more comfortable biopsy procedures.

Read also: